STOCK TITAN

Palisade Bio, Inc. - PALI STOCK NEWS

Welcome to our dedicated page for Palisade Bio news (Ticker: PALI), a resource for investors and traders seeking the latest updates and insights on Palisade Bio stock.

Palisade Bio, Inc. (Symbol: PALI) is a clinical-stage biopharmaceutical company dedicated to developing therapeutic solutions aimed at preserving the integrity of the intestinal barrier. The company's primary focus is on innovative treatments for inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) and Crohn's disease (CD).

Palisade Bio’s strategic product portfolio includes PALI-2108, a promising drug candidate currently under development for treating IBD conditions. The company is also actively researching PALI-1908, a potential therapeutic that may expand its impact in gastrointestinal health.

Recently, Palisade Bio announced significant progress in its pipeline and secured strategic partnerships to further its research and development efforts. Notably, Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the latest offering, underscoring the financial community's confidence in the company's vision and potential.

Palisade Bio's commitment to advancing healthcare solutions is backed by a robust team and dedicated research initiatives. The company frequently updates its stakeholders with the latest developments and forward-looking statements. For more information or inquiries, Jenene Thomas from the JTC Team, LLC can be contacted at 833-475-8247 or via email at PALI@jtcir.com.

Rhea-AI Summary

Palisade Bio announced the successful completion of an analysis demonstrating the potent anti-inflammatory effects of PALI-2108 in treating Ulcerative Colitis (UC). The study showed the superior efficacy of PALI-2108 compared to the approved PDE4 inhibitor apremilast, positioning it as a next-generation therapeutic option for inflammatory bowel disease. The company is set to begin Phase 1 human clinical trials before the end of the year, with promising results from the study conducted in collaboration with Paraza Pharma, Inc.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.41%
Tags
none
-
Rhea-AI Summary
Palisade Bio, Inc. (Nasdaq: PALI) has entered into a strategic collaboration with Strand Life Sciences to advance precision medicine for ulcerative colitis therapy. The partnership grants Palisade Bio access to advanced bioinformatics tools for understanding complex disease pathways and predicting responses to PDE4 inhibitors. Leveraging data from over ten UC clinical studies, Palisade has curated a pipeline of 1600 UC patient samples to identify biomarkers for patient selection using machine learning. This collaboration marks a significant milestone in Palisade Bio's mission to redefine UC treatment through personalized therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.08%
Tags
none
-
Rhea-AI Summary
Palisade Bio successfully demonstrates bioactivation of PALI-2108 in an ex-vivo study of normal healthy and ulcerative colitis patients' stool, showing promising results for the treatment of ulcerative colitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.55%
Tags
none
Rhea-AI Summary
Palisade Bio, Inc. (PALI) to present at the Virtual Investor Lunch Break event, featuring an overview by CEO J.D. Finley and CMO Dr. Mitch Jones. The live webcast on April 16, 2024, will focus on the company's business outlook and opportunities in autoimmune, inflammatory, and fibrotic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.62%
Tags
conferences
-
Rhea-AI Summary
Palisade Bio, Inc. (Nasdaq: PALI) announces the advancement of PALI-2108, a treatment for moderate-to-severe ulcerative colitis, towards Phase 1 clinical study by the end of the year. The company presented at IBD Innovate, discussing the development, differentiation, and clinical pathway of PALI-2108.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.91%
Tags
none
-
Rhea-AI Summary
Palisade Bio, Inc. (Nasdaq: PALI) announces a 1-for-15 reverse stock split to increase per share trading price and comply with Nasdaq listing requirements. The split will be effective on April 5, 2024, with trading under the symbol 'PALI' and new CUSIP number 696389402.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
Rhea-AI Summary
Palisade Bio, Inc. (PALI) progresses PALI-2108 towards Phase 1 clinical study for ulcerative colitis treatment, forms Clinical Advisory Board, and reports financial results for 2023. The company has sufficient cash to achieve milestones into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.11%
Tags
-
Rhea-AI Summary
Palisade Bio, Inc. (PALI) announces acceptance of abstract for poster presentation at DDW 2024 for their novel therapeutic PALI-2108 for ulcerative colitis treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
conferences
-
Rhea-AI Summary
Palisade Bio, Inc. announces a strategic streamlining of the Board to align with current clinical development and corporate vision. The company is advancing PALI-2108 for the treatment of moderate-to-severe ulcerative colitis towards a Phase 1 clinical study, with significant progress in various areas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
none
Rhea-AI Summary
Palisade Bio, Inc. issued a correction to its press release, clarifying the timeline for the PALI-2108 Phase 1 clinical study. The original release incorrectly stated that the study was on track to commence next year, while the company reiterates that it is set to launch in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management

FAQ

What is the current stock price of Palisade Bio (PALI)?

The current stock price of Palisade Bio (PALI) is $1.75 as of December 20, 2024.

What is the market cap of Palisade Bio (PALI)?

The market cap of Palisade Bio (PALI) is approximately 5.3M.

What is Palisade Bio, Inc.'s core business?

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing therapeutics to protect the integrity of the intestinal barrier.

What diseases is Palisade Bio targeting with its therapeutics?

The company focuses on treating inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) and Crohn's disease (CD).

What are the key products in Palisade Bio's portfolio?

Key products include PALI-2108 for IBD treatment and PALI-1908, which is currently in the research phase.

Who is the exclusive placement agent for Palisade Bio's latest offering?

Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering.

How can I contact Palisade Bio for more information?

You can contact Jenene Thomas from the JTC Team, LLC at 833-475-8247 or via email at PALI@jtcir.com.

What stage is Palisade Bio in its development?

Palisade Bio is currently in the clinical stage of developing its therapeutic products.

Does Palisade Bio have any ongoing research projects?

Yes, Palisade Bio is actively researching PALI-1908 in addition to developing PALI-2108 for IBD treatment.

What recent achievements has Palisade Bio announced?

The company has announced significant progress in its drug pipeline and secured strategic partnerships to further research and development.

What is the significance of PALI-2108?

PALI-2108 is a promising drug candidate specifically being developed to treat inflammatory bowel diseases like UC and CD.

Who are the target stakeholders for Palisade Bio's updates?

The target stakeholders include investors, medical professionals, and partners interested in the company's advancements and therapeutic developments.

Palisade Bio, Inc.

Nasdaq:PALI

PALI Rankings

PALI Stock Data

5.35M
1.31M
1.88%
3.58%
2.82%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CARLSBAD